In Brief This Week: Celera, Eureka Genomics, Knome; Genomic Health, and more | GenomeWeb

NEW YORK (GenomeWeb News) – Celera presented data at the annual American Association for Cancer Research meeting describing its mass spectrometry-based approach to identify and validate circulating protein biomarkers that detect non-small cell lung cancer. The company said that one outcome of the study was an immunoassay test for a panel of six biomarkers that detected lung cancer with 94 percent sensitivity and 93 percent specificity in a blinded analysis.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: new chromatin imaging approach, and more.

University of Wisconsin researchers uncover a mutation linked to Mauriac syndrome, which affects some children with type 1 diabetes.

Theranos has hired executives to oversee compliance and regulatory issues, the Wall Street Journal reports.

Chinese researchers to embark on a trial using a CRISPR/Cas9-based immunotherapy next month, Nature News reports.